Company news
Oncolytics Biotech Inc. (NASDAQ:ONCY) news
Oncolytics Biotech Inc. news releases on 6ix. Latest, Sep 29, 2026: Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune…
Press releases & updates
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
September 29, 2026
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
September 28, 2026
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
September 28, 2026
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
September 10, 2026
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
August 18, 2026
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
July 20, 2026
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
July 13, 2026
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
June 16, 2026
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
June 1, 2026
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
May 31, 2026
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
May 25, 2026
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
May 22, 2026
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
May 4, 2026
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
April 26, 2026
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
April 6, 2026
Oncolytics Biotech Completes Domicile Change to the United States
April 2, 2026
Oncolytics Biotech® Completes Domicile Change to the United States
April 1, 2026
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
March 19, 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
March 2, 2026
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
February 24, 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
February 4, 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
February 4, 2026
Oncolytics Biotech Announces Results of Special Meeting of Shareholders
January 16, 2026
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
January 15, 2026
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
January 14, 2026
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
January 12, 2026
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
January 9, 2026
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
January 8, 2026
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
January 6, 2026
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
December 15, 2025
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
December 8, 2025
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
November 19, 2025
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
November 18, 2025
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
November 16, 2025
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
November 3, 2025
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
October 28, 2025
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
October 19, 2025
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
September 28, 2025
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
September 15, 2025
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
September 7, 2025
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
September 1, 2025
Oncolytics Biotech® Announces Upcoming Investor Conferences in September
August 28, 2025
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
August 26, 2025
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
August 14, 2025
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
August 14, 2025
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
August 11, 2025
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
August 11, 2025
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
August 8, 2025
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
August 8, 2025
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
August 5, 2025